C-AHHAumbilical cord blood-derived MSCs, regenerative medicine, stem cell therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Medipost umbilical cord blood-derived MSCs, regenerative medicine, stem cell therapeutics
MEDIPOST says its mission is to help patients with incurable diseases and unmet medical needs through stem cells and regenerative medicine. The company commercialized CARTISTEM, described as the world's first regulatory-approved allogeneic human umbilical cord blood-derived mesenchymal stem cell product for knee osteoarthritis, launched in Korea in 2012. Its business also includes CELLTREE cord blood banking, CDMO services, and MOVITA nutritional supplements.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Medipost — Near-term readout · Lower middle. Derived deterministically from 10 extracted project(s). Most-advanced status: approved. Band: near_readout. Modifiers: +5 depth (4 programs at approved);…
Source: Deterministic